CC49

Antibody Name: CC49
References: Kashmiri, S.V.S., Shu, Liming, S., Padlan, E.A., Milenic, D.E., Schlom, J. and Hand, P.H. "Generation, characterization and in Vivo studies of humanized anticarcinoma antibody CC49" Hydriboma (1995) 14:461-473.
Donor Antibody: mouse
Acceptor Antibody: Human IgG1 | k
Antigen: Tumor-associated glycoprotein (TAG)-72, human pancarcinoma antigen.
Laboratory: National Institutes of Health, MA
Design: Looked at structures most homologous to VH and VL sequences. Chose FRs based on homology with residues deemed to be important for maintaining the combining site structure.
Frameworks: VH 21/28'CL | VL LEN
CDRs: All 6 VH and VL, Kabat Definition.
Backmutations: VH K12V V20I R38K A40N M48I RV66-67KA I69L R71A M80V Y91F A93T
VL T5S A19V I21L P43S L78V Q100A I106L
Binding: Relative affinity constant was 2- to 3-fold less than those of mouse and chimaeric mAbs (30-fold more humanised mAb needed). Similar tumour-targeting properties to the chimaeric mAb.
Expression: Sp2/0
Comment: mouse mAb has a higher binding affinity than B72.3
Clinical Indication: Diagnosis and therapy of human carcinomas.

explanation of symbols and abbreviations

José Saldanha © 1997-8. Birkbeck College, London WC1E 7HX.